PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies. The impact of these therapies is attributed to the plasma lipid-lowering effect induced when LDLR hepatic expression levels are recovered after the...
Main Authors: | Aureli Luquero, Lina Badimon, Maria Borrell-Pages |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.639727/full |
Similar Items
-
CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
by: Christian Abendstein Kjellmo, et al.
Published: (2018-05-01) -
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01) -
Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01) -
Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞
by: Shilpa Pandit, et al.
Published: (2008-06-01) -
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
by: Greg Welder, et al.
Published: (2010-09-01)